NCT04351295已完成2 期
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- Number of patients with mortality or need for mechanical ventilation
研究概览
简要总结
Faviprevir in COVID-19 treatment
详细描述
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with covid 19
排除标准
- •Allergy or contraindications to faviprevir
研究组 & 干预措施
Faviprevir
Experimental
Faviprevir
干预措施: Favipiravir (Drug)
chloroquine
Active Comparator
chloroquine
干预措施: Chloroquine (Drug)
结局指标
主要结局
Number of patients with mortality or need for mechanical ventilation
时间窗: 6 months
Number of patients with mortality or need for mechanical ventilation
次要结局
未报告次要终点
研究者
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Tanta University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of BangladeshCOVID-19Favipiravir (Favipira)NCT04402203Bangladesh Medical Research Council (BMRC)50
进行中（未招募）
1 期
Safety and Efficacy of Favipiravir in COVID-19 Patients with Pneumonia-A randomized, double blind, placebo- controlled studyPatients diagnosed with COVID-19 by positive PCR for SARS-COV2MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-002753-22-ESFerrer Internacional, S.A.100
已完成
3 期
Favipiravir in High-risk COVID-19 PatientsCovid19NCT04818320Penang Hospital, Malaysia500
已完成
3 期
Remdesivir Efficacy In Management Of COVID-19 PatientsCovid19NCT04853901Ain Shams University77
招募中
2 期
ANIF1 effect on COVID-19COVID-19.COVID-19, virus identifiedU07.1IRCT20190727044343N3Mazandaran University of Medical Sceinces60